Af­ter win­ning an ear­ly deal on XO1, the vir­tu­al biotech gang gets back to­geth­er for Su­perX

A lit­tle less than two years af­ter J&J swooped in to snag the pre­clin­i­cal an­tithrom­bin drug at XO1 in the UK, the vir­tu­al team of en­tre­pre­neurs who cre­at­ed that as­set-cen­tered ven­ture is back to­geth­er again. This time they’re op­er­at­ing as Su­perX, and they’re work­ing in a very fa­mil­iar re­search space.

With a very fa­mil­iar bud­get.

Like XO1, Su­perX is get­ting a liftoff with an $11 mil­lion round — this time drawn from Medicxi and part­ners at John­son & John­son In­no­va­tion. Uni­ver­si­ty of Cam­bridge Pro­fes­sor Jim Hunt­ing­ton is the CSO. Trevor Baglin is the CMO. X01 co-founder and Medicxi part­ner David Grainger is on the team, along with Kevin John­son, al­so at Medicxi, tak­ing the chair­man’s role. XO1 vets Bob Schroff will be op­er­a­tions chief with Jo Davies once again han­dling the in­tel­lec­tu­al prop­er­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.